
Novavax Inc (NASDAQ:NVAX) shares are trading lower Thursday following reports that the U.S. Food and Drug Administration's decision on the company's COVID-19 vaccine could be delayed to review manufacturing changes.
According to a CNBC report, citing an agency spokesperson, the FDA needs to review recent adjustments to Novavax's manufacturing process before it can authorize the company's vaccine.